Society of Nuclear Medicine Honours Peter J. Ell

"With this award, the SNM recognises Dr. Ell's pioneering efforts in laying the foundations of nuclear medicine and molecular imaging in Europe," said Alexander J. McEwan, who served as president of the Society of Nuclear Medicine (SNM) from 2007 to 2008. "He has blazed a trail in nuclear medicine and created the climate for research and development that exists in Europe today."

Ell was also recognised for his efforts in advancing molecular imaging and developing clinical applications of single photon emission computed tomography (SPECT). He pioneered the use of HMPAO, a radiopharmaceutical tracer compound used to detect regional cerebral blood. This tracer can present physicians with a portrait of blood flow in the brain and indicate the existence of heart disease and inflammatory bowel disease.

Along with other researchers, Ell initiated the use of immunoglobulin G, a type of antibody that circulates in the blood and recognises foreign particles that might be harmful, as well as iodobenzamide, a radiolabeled probe that binds to the cerebral dopamine receptor and is used in neurotransmission studies and SPECT.

Ell is a founding member of the European Association of Nuclear Medicine (EANM). In addition to serving as its first secretary, he was elected president of EANM in 1994 and served in this capacity for three years. Under his leadership, EANM's executive committee established the European School of Nuclear Medicine.

For 13 years, Ell was also editor-in-chief of the European Journal of Nuclear Medicine and Molecular Imaging, transforming it into a major, high-quality publication. He has written articles on and taught in areas as diverse as neurology, hepatology, skeletal pathology, oncology and psychiatry.

MEDICA.de; Source: Society of Nuclear Medicine